VALUE ASSESSMENT – “HOW TO VALUE A COMPANY OR A PROJECT”
When an R&D project moves along the development pathway, science eventually meets business and questions arise concerning valuation and market value of the project.
This is particularly critical for projects that require external and VC funding and move to form startups. But how is such a project/ a company valued, particularly after maturing to become a late-stage R&D pharmaceutical project?
This lecture will first introduce key dimensions of assessing and evaluating late stage pharmaceutical R&D projects. Dimensions include the content for Target Product Profile, Technical Risk Assessment, Commercial Forecast and Financial Valuation. To conclude, the lecture will outline how the Financial Value of a company is composed of projects and other elements. Matthias Krings is Founder of Catenion, a management consulting firm devoted to helping pharmaceutical and medical products companies create more innovative and effective strategies and organizations. Matthias has been active in the field for the past 20 years and will give us a high-level overview of what you need to be prepared for when your company is being valued.Quelle: Spark Berlin